Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 5/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23729451 | 0.88 | TSHR (0.51) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL27115230 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL29221102 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL26297961 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL17346257 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL21738833 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL26297950 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL24229748 | 0.86 | OTC (0.49) | TSHRKDM4ELMNAHPGDMEN1 | |
| SCHEMBL31746997 | 0.86 | GLP1R (0.37) | TSHRKDM4ELMNAHPGDALDH1A1 | |
| SCHEMBL25009846 | 0.85 | TSHR (0.45) | TSHRKDM4ELMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038373-A1 | STABILE CONJUGATE | CD2, TTL, DDOST | TSHR 1371/4885KDM4E 3642/4885LMNA 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.